Newsroom

Download PDF CAMBRIDGE, Mass., Apr 13, 2010 (BUSINESS WIRE) –AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that preclinical data from its translational research platform and antibody pipeline will be presented during six poster sessions at the American Association for Cancer Research (AACR) 101st Annual Meeting

Download PDF CAMBRIDGE, Mass., April 1, 2010 –(BUSINESS WIRE)–AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO – News), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that the underwriters of its recently completed initial public offering of common stock have exercised their option to purchase an additional 968,539 shares of common stock to

Download PDF CAMBRIDGE, Mass., Mar 18, 2010 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced the completion of its initial public offering of 9,000,000 shares of its common stock. All shares were sold at an initial public offering price of $9.00 per

Download PDF CAMBRIDGE, Mass., Mar 11, 2010 (BUSINESS WIRE) — AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO), a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced the pricing of its initial public offering of 9,000,000 shares of its common stock at $9.00 per share, before underwriting discounts and commissions. All of the common

Download PDF CAMBRIDGE, Mass., February 22, 2010 – AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced it has initiated enrollment in a global Phase 3 clinical trial for its oral, triple VEGF receptor inhibitor, tivozanib, in advanced renal cell cancer (RCC). This Phase 3 clinical trial, named

Download PDF CAMBRIDGE, Mass., December 16, 2009—AVEO Pharmaceuticals, Inc. today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to the proposed initial public offering of shares of its common stock. The number of shares to be offered and the price range for the

Download PDF Preclinical Combination Data Also Presented, Demonstrate mTOR-Tivozanib Combination in Breast Tumor Model Prevents Emergence of Resistance CAMBRIDGE, Mass., November 17, 2009 – AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced preliminary results from a Phase 1 clinical study evaluating its oral, triple VEGF receptor inhibitor

Download PDF CAMBRIDGE, Mass., September 16, 2009 – AVEO Pharmaceuticals, Inc., a biopharmaceutical company leveraging breakthrough discoveries in cancer biology to discover, develop and commercialize targeted oncology therapies, today announced the appointment of William J. Slichenmyer, M.D., Sc.M., to the position of chief medical officer. Dr. Slichenmyer brings 15 years’ experience leading the clinical development